Phase 1 trial findings confirm safety and tolerability of Huons’ dry eye therapy | Optometry Times - Clinical News

Published on December 5, 2025
HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.
Continue reading on website
Other news

Crafting your own eyewear brand: Success starts with personalization | Optometry Times - Clinical News

December 5, 2025

How to put wearable virtual reality technology to work in your practice | Optometry Times - Clinical News

December 8, 2025
VR technology captures not only visual fields but a full “stack” of pretest results.